Pandemic Patients header logo.

April 14, 2022 – R.T. Asked: When Can I Get the COVID-19 Booster After Receiving Monoclonal Antibodies?

On April 14, 2022, R.T. Asked:

“When should immunocompromised patients get their second COVID-19 vaccine booster after receiving monoclonal antibodies? We are getting conflicting information from doctors, the news, medical literature, and hospitals on whether it is safe to receive a COVID-19 vaccine or vaccine booster after receiving monoclonal antibodies and whether doing this will reduce the efficacy of the vaccine. We are in a quandary, not knowing what to do.”


Specific data does not yet exist about the interaction between monoclonal antibodies and the COVID-19 vaccines because monoclonal antibodies for COVID-19 are new and currently subject to Emergency Use Authorization through the U.S. Food and Drug Administration (FDA). There is little data currently available about the safety of monoclonal antibodies and subsequent vaccination. Everyone is different, so we encourage meeting with your health care provider to analyze the risks and benefits of getting a COVID-19 vaccine following the administration of monoclonal antibodies.

Generally, monoclonal antibodies are given to immunocompromised patients to provide additional passive immunity because their body is unable to mount a full amnestic response to the invasive pathogen (in this case, SARS-CoV-2). For most people, in the absence of a known exposure to COVID-19, it is appropriate to get the COVID-19 vaccine or vaccine booster when it is due. Some people may choose to delay getting a COVID-19 vaccine or vaccine booster because they may retain some level of protection from the monoclonal antibodies for up to approximately 8 months after receiving monoclonal antibodies. To determine your current level of immunity against COVID-19, you can receive a COVID-19-specific quantitative IgG Ab blood test. A patient can request this test from their health care provider, and the test’s results can help guide informed treatment decisions on a case-by-case basis.

An important distinction between monoclonal antibodies and the COVID-19 vaccines is that they may perform differently against a new emerging strain of the virus. In some situations, the vaccines may offer some protection that monoclonal antibodies do not, and in other situations, the reverse may be true. While some patients may choose to delay receiving a COVID-19 vaccine because they currently have some level of protection offered by monoclonal antibodies, other patients may choose to receive the COVID-19 vaccine when it is due because receiving it alongside monoclonal antibodies could provide more robust protection against COVID-19 and future variants.

If you are still unsure about whether it is safe to receive the COVID-19 vaccine or vaccine booster, based on your individual circumstances, we encourage you to continue taking other measures to protect yourself against COVID-19. Most importantly, you should maintain physical distance from other people, wear a face mask, and wash your hands frequently. Review our COVID-19 Safety Guide for more tips on how to protect yourself against COVID-19.

Click here to access other COVID-19 FAQ.

P.M. Asked: Can I Negotiate Remote Work as a Condition of Employment if I am Immunocompromised?

“I am immunocompromised and thinking of switching jobs. Because of my compromised immune system, I need to work remotely during the coronavirus pandemic to avoid exposure to COVID-19. My current employer allows me to work remotely as a reasonable accommodation, but I don’t want to move to another job if they will not provide it. How can I negotiate remote work as a reasonable accommodation from a prospective employer as a condition of employment?”

Continue Reading...

FDA Authorizes First Vaccine Booster for Children 5-11

On May 17, 2022, the U.S. Food and Drug Administration (FDA) amended the Emergency Use Authorization (EUA) for the Pfizer-BioNTech COVID-19 vaccine (marketed as Comirnaty) to authorize the use of a single booster dose for children between the ages of five and eleven. The FDA authorized the administration of this booster at least five months after the completion of the primary vaccination series with the same vaccine.

Continue Reading...

Pandemic Patients is a 501(c)(3) non-profit organization that works to relieve the harm caused by COVID-19 and post-COVID conditions. EIN 86-3930257.

Please consider making a charitable donation to help us advance our important work.

Prior to using this website, please review our Terms of Use and Privacy Policy.